📊 MYO Key Takeaways
Is Myomo, Inc.. (MYO) a Good Investment?
MyoMo exhibits fatal fundamental weaknesses despite impressive 25.7% revenue growth and excellent 65.7% gross margins. Operating losses of -14.4M and negative free cash flow of -16.3M are accelerating capital destruction, with zero YoY profitability improvement suggesting structural business model problems. At current burn rate, the company has <1 year of cash runway and faces severe dilution risk.
MYOMO shows strong revenue growth and a high gross margin, but remains deeply unprofitable with substantial negative free cash flow and worsening EPS. Leverage and severely negative interest coverage, alongside limited cash relative to annual burn, create near-term financing/dilution risk before scale is achieved. Fundamentals warrant caution until operating efficiency improves and cash burn moderates.
Why Buy Myomo, Inc.. Stock? MYO Key Strengths
- Strong revenue growth at 25.7% YoY demonstrates market demand and adoption
- Exceptional gross margin of 65.7% indicates superior product economics and pricing power
- Adequate near-term liquidity with 3.30x current ratio and $14.1M cash position
- 25.7% revenue growth indicating demand expansion
- High 65.7% gross margin supports potential operating leverage
- Solid liquidity with 3.30x current and 2.93x quick ratios
MYO Stock Risks: Myomo, Inc.. Investment Risks
- Operating margin of -35.2% and net margin of -38.1% show severe profitability breakdown despite revenue growth
- Operating cash flow of -14.5M annually with negative FCF of -16.3M indicating unsustainable business model
- No YoY profitability improvement despite 25% revenue growth suggests inability to scale operations efficiently, signaling fundamental operational or cost structure problems
- Limited cash runway of approximately 12 months at current burn rate necessitates immediate capital raise or restructuring
- Shareholder value destruction with ROE of -136.6% and EPS deteriorating 131.2% YoY
- Persistent operating and net losses (-35% and -38% margins)
- Negative free cash flow and short runway versus cash on hand
- High leverage (0.98x D/E) and negative interest coverage increase refinancing/dilution risk
Key Metrics to Watch
- Operating cash flow trend toward breakeven - critical survival metric
- Operating expense leverage and path to gross profit coverage of OpEx
- Gross margin sustainability as revenue scales
- Cash runway timeline and dilutive capital raising necessity
- Sequential quarterly profitability inflection or deterioration confirmation
- Operating cash flow (quarterly) / burn rate
- Operating margin trajectory toward break-even
Myomo, Inc.. (MYO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.30x current ratio provides a solid financial cushion.
MYO Profit Margin, ROE & Profitability Analysis
MYO vs Healthcare Sector: How Myomo, Inc.. Compares
How Myomo, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Myomo, Inc.. Stock Overvalued? MYO Valuation Analysis 2026
Based on fundamental analysis, Myomo, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Myomo, Inc.. Balance Sheet: MYO Debt, Cash & Liquidity
MYO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Myomo, Inc..'s revenue has grown significantly by 195% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.16 indicates the company is currently unprofitable.
MYO Revenue Growth, EPS Growth & YoY Performance
MYO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.2M | -$966.4K | $-0.03 |
| Q2 2025 | $7.5M | -$1.1M | $-0.03 |
| Q1 2025 | $3.8M | -$3.5M | $-0.08 |
| Q3 2024 | $5.1M | -$966.4K | $-0.03 |
| Q2 2024 | $6.0M | -$1.0M | $-0.03 |
| Q1 2024 | $3.4M | -$2.6M | $-0.10 |
| Q3 2023 | $4.0M | -$1.0M | $-0.06 |
| Q2 2023 | $3.7M | -$1.0M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Myomo, Inc.. Dividends, Buybacks & Capital Allocation
MYO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Myomo, Inc.. (CIK: 0001369290)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MYO
What is the AI rating for MYO?
Myomo, Inc.. (MYO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MYO's key strengths?
Claude: Strong revenue growth at 25.7% YoY demonstrates market demand and adoption. Exceptional gross margin of 65.7% indicates superior product economics and pricing power. ChatGPT: 25.7% revenue growth indicating demand expansion. High 65.7% gross margin supports potential operating leverage.
What are the risks of investing in MYO?
Claude: Operating margin of -35.2% and net margin of -38.1% show severe profitability breakdown despite revenue growth. Operating cash flow of -14.5M annually with negative FCF of -16.3M indicating unsustainable business model. ChatGPT: Persistent operating and net losses (-35% and -38% margins). Negative free cash flow and short runway versus cash on hand.
What is MYO's revenue and growth?
Myomo, Inc.. reported revenue of $40.9M.
Does MYO pay dividends?
Myomo, Inc.. does not currently pay dividends.
Where can I find MYO SEC filings?
Official SEC filings for Myomo, Inc.. (CIK: 0001369290) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MYO's EPS?
Myomo, Inc.. has a diluted EPS of $-0.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MYO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Myomo, Inc.. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MYO stock overvalued or undervalued?
Valuation metrics for MYO: ROE of -136.6% (sector avg: 15%), net margin of -38.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MYO stock in 2026?
Our dual AI analysis gives Myomo, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MYO's free cash flow?
Myomo, Inc..'s operating cash flow is $-14.5M, with capital expenditures of $1.7M. FCF margin is -39.7%.
How does MYO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -38.1% (avg: 12%), ROE -136.6% (avg: 15%), current ratio 3.30 (avg: 2).